Valuation: Patrys Limited

Market Cap 23.33M 16.69M 14.3M 13.38M 12.23M 23.09M 1.6B 158M 61.57M 802M 62.67M 61.31M 2.66B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 16.16M 13.85M 12.96M 11.84M 22.35M 1.55B 153M 59.61M 777M 60.67M 59.36M 2.57B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 day-3.03%
Current month-3.03%
1 month-13.51%
3 months-13.51%
6 months-8.57%
Current year+14.29%
1 week 0.03
Extreme 0.032
0.03
1 month 0.03
Extreme 0.031
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.014999
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.56
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 2026-02-15
Chief Operating Officer - 2012-05-31
Corporate Secretary - 2025-11-09
Director TitleAgeSince
Director/Board Member - 2025-06-16
Chairman 64 -
Director/Board Member - 2025-11-09
Date Insider Type Main position Quantity % Market Cap.
8/11/23 Expiration

Chief Executive Officer

396,132 0.0193%
8/11/23 Expiration

Chief Executive Officer

3,283 0.0002%
12/6/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%0.00%+42.23%-73.33% 15.77M
-4.31%-6.62%+65.79%+98.02% 72.12B
-4.19%+1.05%+52.79%+85.53% 65.85B
-3.22%+23.17%+1.75%-5.23% 29.28B
-1.42%-3.38%-5.99%+465.34% 27.47B
-4.71%+5.29%+47.63%+8.97% 26.7B
-1.81%+0.38%+34.52%-18.33% 20.06B
+5.36%+4.61%+270.18%+415.10% 18.22B
-2.79%+0.10%+12.09%+549.69% 16.4B
+0.87%+4.26%+41.21%+150.80% 13.4B
Average -1.92%+5.46%+56.22%+167.66% 28.95B
Weighted average by Cap. -2.83%+3.13%+54.39%+151.29%

Financials

2024 2025
Net sales 1.39M 997K 855K 800K 731K 1.38M 95.5M 9.46M 3.68M 47.95M 3.74M 3.66M 159M 829K 593K 508K 475K 434K 820K 56.75M 5.62M 2.19M 28.5M 2.23M 2.18M 94.29M
Net income -3.54M -2.53M -2.17M -2.03M -1.86M -3.5M -242M -24.02M -9.34M -122M -9.51M -9.3M -403M -3.01M -2.16M -1.85M -1.73M -1.58M -2.98M -206M -20.45M -7.95M -104M -8.09M -7.92M -343M
Net Debt -2.24M -1.6M -1.37M -1.29M -1.17M -2.22M -153M -15.21M -5.91M -77.07M -6.02M -5.89M -255M -742K -531K -455K -426K -389K -735K -50.86M -5.04M -1.96M -25.54M -1.99M -1.95M -84.49M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
26-08-24 A$0.0320 -3.03% 35,294
26-08-21 A$0.0330 0.00% 250
26-08-20 A$0.0330 +3.13% 238,219
26-08-19 A$0.0320 0.00% 3,374
26-08-18 A$0.0320 0.00% 1